Updated June 2026 · ClinicalTrials.gov
National Heart, Lung, and Blood Institute (NHLBI)
10 clinical trials · 10 recruiting · NIH
National Heart, Lung, and Blood Institute (NHLBI) has 10 clinical trials registered on ClinicalTrials.gov, with 10 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About National Heart, Lung, and Blood Institute (NHLBI)\'s Trial Portfolio
National Heart, Lung, and Blood Institute (NHLBI) is a federal-government sponsor. Government-funded trials, including those from the National Institutes of Health, are typically focused on public-health priorities, rare-disease research, and questions where commercial sponsors have less incentive to fund. They are also among the most rigorously documented trials on ClinicalTrials.gov.
10 of National Heart, Lung, and Blood Institute (NHLBI)'s 10 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
National Heart, Lung, and Blood Institute (NHLBI)'s research footprint spans Tuberous Sclerosis (2 trials), Cystic Fibrosis (2), and Sickle Cell Disease (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
is the largest single phase in National Heart, Lung, and Blood Institute (NHLBI)'s portfolio at 70% of registered trials. The full phase breakdown appears in the sidebar.
Trials by National Heart, Lung, and Blood Institute (NHLBI)
Study of the Disease Process of Lymphangioleiomyomatosis
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and...
Natural History Study of CADASIL
Background: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood...
Natural History of Sickle Cell Disease
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research...
Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement
Background: Kohlmeier-Degos (KD) is a rare disease that causes inflammation and blood clots, leading to blockages in small blood vessels. These blockages can result in K-D...
Causes and Natural History of Dyslipidemias
This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the...
Role of Genetic Factors in the Development of Lung Disease
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung...
Natural History of Bronchiectasis
Background: * Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiectasis have a history...
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the...
Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate...
Background: Some people with the same disorder on a genetic level have more complications than others. Researchers want to look for a link between the PKLR gene and sickle cell...
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell...
Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening...
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does National Heart, Lung, and Blood Institute (NHLBI) have on ClinicalTrials.gov?
National Heart, Lung, and Blood Institute (NHLBI) has 10 clinical trials registered on the federal ClinicalTrials.gov registry, of which 10 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does National Heart, Lung, and Blood Institute (NHLBI) study?
National Heart, Lung, and Blood Institute (NHLBI)'s registered trials cover 20 conditions on ClinicalTrials.gov, led by Tuberous Sclerosis (2 trials), Cystic Fibrosis (2 trials), Sickle Cell Disease (2 trials), Lung Disease (1 trial), Pneumothorax (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a National Heart, Lung, and Blood Institute (NHLBI) clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Other Trial Sponsors
87 trials · 87 recruiting
58 trials · 58 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
47 trials · 47 recruiting
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-06-26 · 10 trials tracked for National Heart, Lung, and Blood Institute (NHLBI).